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Abstract 
Introduction: Age-related hypogonadism in men leads to abnormal body composition 
development and overproduction of inflammatory cytokines, and thus has atherogenic and 
potentially cancer promoting effects. The aim of the study was to assess the effect of age-
dependent testosterone deficiency replacement in men on body composition, serum leptin, 
adiponectin, and C-reactive protein levels.  
Material and methods: Men aged 50–65 years (56.0 ± 5.7, average ± SD), with total 
testosterone levels < 4 ng/mL, and clinical symptoms of hypogonadism were divided into two 
groups of 20 men and treated with testosterone (200 mg/two weeks intramuscularly) or placebo 
during 12 months. 
Results: Twelve months of treatment with testosterone led to body mass index (BMI) and fat 
mass (FM) decrease from 26.6 ± 2.1 to 26.1 ± 1.8 kg/m2, p < 0.05, and from 17.0 ± 4.4 to 15.6 
± 4.0 kg, p < 0.05, respectively. Body mass index and FM did not change in placebo-receiving 
subjects. Serum leptin and highly selective C-reactive protein (hsCRP) levels in testosterone 
group decreased from 6.2 ± 1.4 to 4.0 ± 1.2 μg/L, p < 0.05, and from 1.4 ± 1.2 to 1.0 ± 1.0 
mg/L, p < 0.05 after 12 months, respectively. Adiponectin increased from 7.6 ± 2.5μg/mL to 
9.4 ± 2.8 μg/mL, p < 0.05 in the same time. In the placebo group serum leptin, adiponectin, and 
hsCRP levels did not change significantly. 
Conclusions: Testosterone replacement in men with age-related hypogonadism causes 
a decrease in body mass index, fat mass, serum leptin, and C-reactive protein levels and 
increases serum adiponectin levels. 
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Introduction 
Age-related hypogonadism in men leads to changes in body composition: a decrease in 
fat-free mass and gain of fat mass, dysfunction of many organs, and poor quality of life [1]. 
Increased fat mass results in overproduction of leptin and inflammatory cytokines and a state 
of chronic inflammation. Elevated leptin interferes with endothelial dysfunction, increases 
platelet adhesion, and stimulates the migration and proliferation of smooth muscle cells, and 
thus has atherogenic effects [2]. Moreover, hyperleptinaemia potentially promotes cancer 
development [3]. On the other hand, adiponectin — a cytokine with beneficial metabolic 
properties — exhibits vasoprotective effects [4, 5]. C-reactive protein (CRP) is involved in 
atherosclerotic plaque formation and is considered as an independent risk marker for acute 
coronary incidents [6, 7]. 
The goal of the study was to assess the effect of age-dependent testosterone deficiency 
replacement in men on body composition, serum leptin, adiponectin, and C-reactive protein 
levels.  
 
Material and methods 
Forty men aged 50–65 years (56.0 ± 5.7, average ± SD), who visited the outdoor clinic 
of the Endocrinology Department of the Medical Centrum for Postgraduate Studies (MCPS, 
Warsaw) due to clinical manifestations suggesting hypogonadism: erectile dysfunction, libido 
decline, hot flashes, abnormal sleep, and loss of self-confidence. In all subjects in two 
consecutive morning blood samples total testosterone levels < 4 ng/mL were found, and detailed 
clinical and laboratory studies were performed. 
Exclusion criteria included: 
— primary and secondary hypogonadism caused by hypothalamic-pituitary-testis axis 
diseases; 
— taking medications that affect testosterone levels; 
— obesity (body mass index [BMI] ≥ 30 kg/m2); 
— diseases: poorly controlled hypertension, coronary artery disease, heart failure, diabetes 
mellitus, serious liver disease, chronic renal disease, cancer, severe depression requiring 
pharmacological treatment; 
— haematocrit > 54%, 
— serum prostatic specific antigen (PSA) > 4 ng/mL. 
Candidates were informed about the purpose of the study, and they gave their written consent. 
The subjects were divided into two groups of 20 men similar of age, height, weight, and clinical 
features of hypogonadism. One group was treated with testosterone and the other was 
considered as a control group. Treated individuals received testosterone enanthane 
(Testosteronum Prolongatum® Jelfa, ampoules 100 mg in 1 mL) at a dose of 200 mg 
intramuscularly every two weeks. The control group was given a placebo (ampoules of 1 mL 
containing 0.9% NaCl, identical to the original preparation), also administered intramuscularly 
every two weeks. 
The study project received a positive evaluation of the MCPS Bioethics Commission. 
In each participant initially and after 3 and 12 months of treatment a clinical examination was 
performed with assessment of BMI. A blood sample was taken to determine total testosterone 
(TT), luteinising hormone (LH), follicle-stimulating hormone (FSH), leptin, and highly 
selective C-reactive protein (hs-CRP) levels. Blood samples for hormonal tests were taken 
fasting at 08.00 in the seventh day after administration of testosterone or placebo [8]. The body 
composition and the adiponectin levels were determined initially and after 12 months. To 
monitor the safety of testosterone treatment morphology, prostate-specific antigen (PSA) 
levels, palpate, and ultrasonographic prostatic gland (TRUS) examinations were performed in 
all subjects every six months. 
 
Assays 
Blood samples were taken from the elbow vein using TERUMO kits. 
Morphology: the assay was performed within four hours using a Sysmex SF-300 analyser 
(Sysmex Corp, Japan). Adiponectin, FSH, LH, hsCRP, leptin, and TT: approx. 9 mL for tubes 
without anticoagulant, after blood clotting within 30 to 60 minutes the blood was centrifuged 
for five minutes at approx. 4500 rpm. Part of the assays were performed using Hitachi 912, 
Elecsys 2010, and Immulite 2000 analysers on the day when the blood samples were taken. For 
the other assays, serum was stored in samples of 100–200 µL at –200ºC according to the 
recommendations of kits’ manufacturers. 
Highly selective C-reactive protein was determined by immunoturbidimetry using a Hitachi 
912 (Roche Diagnostics, Switzerland) analyser; PSA by immunoelectrochemiluminescence 
method (Elecsys 2010 Analyzer, Roche Diagnostics, Switzerland); FSH and LH by enzymatic 
immunoassay (Immulite 2000, dPC, USA); TT by the method of radioimmunoassay (RIA) 
using the TESTO-CT2 (Cis Bio International, France); adiponectin by RIA (Adiponectin RIA 
Kit, LINCO Research Inc., USA); and leptin by RIA (Human Leptin RIA Kit, LINCO Research 
Inc., USA). 
Body composition separately in body regions was assessed by dual-energy X-ray 
absorptiometry method (DXA) using a General Electric DPX device. [9]. 
 
Statistical analysis 
The results are presented as the mean value and standard deviation scores (x ± SD, for 
numerical parameters), and the number and percentage of subjects that were examined in whom 
the characteristics occurred (for categorical parameters). Comparisons of the significance of 
changes before and after treatment were performed with Wilcox tests. Comparisons between 
groups on each visit were performed using the Mann-Whitney test. A p value of 0.05 was 
assumed to be statistically significant in all calculations. All calculations were performed using 
the R 3.3.1 statistical package. 
 
Results 
The baseline characteristics of participants are shown in Table 1. 
 
Effects of treatment on testosterone, LH, and FSH levels 
Testosterone supplementation caused an increase in serum total testosterone and a 
decrease in serum LH and FSH levels after 12 months: from 3.1 ± 0.4 (mean ± SD) to 7.2 ± 1.3 
ng/mL, from 4.0 ± 2.2 to 0.5 ± 0.6 U/L, and from 7.5 ± 3.4 to 0.9 ± 1.0 U/L, respectively, p < 
0.001 in all cases. In the placebo group the levels of total testosterone, LH, and FSH after 12 
months were 3.3 ± 0.5 ng/mL, 4.4 ± 1.4 U/L, and 6.3 ± 1.8 U/L, respectively; p < 0.001, 
compared to testosterone-treated subjects in all cases. 
 
Effects of treatment on body weight and body composition 
Treatment with testosterone led to weight loss from 78.3 ± 6.3 to 77.0 ± 5.7 kg after 12 
months, p < 0.05; there was no difference compared to the placebo group. At the same time the 
BMI in the treated group decreased from 26.6 ± 2.1 to 26.1 ± 1.8 kg/m2, p < 0.05; there was 
also no difference in comparison to the placebo group. After 12 months the fat mass (FM) in 
the treated group decreased from 17.0 ± 4.4 to 15.6 ± 4.0 kg, p < 0.05, and in the placebo group 
it increased from 19.1 ± 4.9 to 19.9 ± 5.2 kg, p < 0.05. After 12 months the FM was lower in 
the testosterone-treated group compared to the placebo group, p = 0.005. 
 
Effects of treatment on serum leptin, adiponectin, and C-reactive protein 
Testosterone treatment resulted in a decrease in leptin levels already after three months 
from 6.2 ± 1.4 to 4.5 ± 1.5 μg/L, p < 0.05 and to 4.0 ± 1.2 μg/L, p < 0.05 after 12 months 
(decrease of 35%). In the placebo group leptin levels after 12 months were 6.9 ± 2.8 μg/L; p < 
0.001, compared to the testosterone-treated group. Adiponectin after 12 months of testosterone 
increased from 7.6 ± 2.5 μg/mL to 9.4 ± 2.8 μg/mL, p < 0.05. In the placebo group adiponectin 
levels after 12 months were 6.5 ± 2.1 μg/mL; p = 0.001, compared to the testosterone-treated 
group. Highly selective C-reactive protein levels in the testosterone-treated subjects decreased 
over a period of 12 months from 1.4 ± 1.2 to 1.0 ± 1.0 mg/L, p < 0.05. Changes in leptin, 
adiponectin, and hsCRP levels during 12 months in both groups are presented in Table 2, 
Figures 1 and 2. 
 
Correlations between serum leptin levels, adiponectin levels, and selected parameters 
The results of univariate analysis of regression between leptin and adiponectin levels 
and the selected parameters initially and after 12 months of treatment in both groups are shown 
in Table 3. 
Baseline leptin levels in both groups positively correlated with body weight (BW), BMI, fat 
mass (FM), fat mass of the trunk (FMt), and CRP. After 12 months, in the testosterone-treated 
group leptin correlated positively only with FM. Baseline levels of adiponectin in both groups 
negatively correlated with BW, BMI, FM, FMt, CRP, and leptin (Fig. 3). After 12 months, in 
the testosterone group the negative correlation was maintained in relation to BW, BMI, and 
CRP. 
 
Safety of treatment 
None of the subjects experienced adverse impact of testosterone or placebo on the 
course of co-existing diseases. Prostate-specific antigen levels increased within 12 months in 
the testosterone-treated and the placebo group: from 0.9 ± 0.4 to 1.2 ± 0.5 ng/mL, p < 0.05, and 
from 0.9 ± 0.5 to 1.1 ± 0.5 ng/mL, p < 0.05, respectively. Differences between the groups were 
not statistically significant at any time point. The haematocrit increased at the same time in both 
groups; however, in the testosterone group this increase was higher (from 44.6 ± 2.7 to 48.2 ± 
2.5%, p < 0.05) and the differences between the two groups at 12 months were significant 
(placebo group 44.7 ± 3.0%, p < 0.001). 
 
Discussion 
A decrease in testosterone secretion significantly contributes to changes in the body 
composition of the aging male [10]. Fat-free mass decreases and enhancement of fat mass is 
observed. Adipose tissue starts to produce proinflammatory cytokines. Serum leptin and CRP 
are higher, and adiponectin levels decrease [11]. Lowering of the energy expenditure and 
insulin sensitivity associated with obesity lead to metabolic syndrome development and 
augmentation of cardiovascular risk. In our study we demonstrate that 12-month testosterone 
supplementation reduces fat mass, significantly lowers leptin levels, and increases adiponectin 
levels. 
After three months of therapy we found a significant reduction in serum leptin levels, 
and this trend was continued in the following months. In contrast, during the 12 months leptin 
levels in the placebo group increased by 15%. Similar results were obtained by Luukkaa et al. 
in young healthy males who used 200 mg of testosterone intramuscularly once weekly for 12 
months as a contraceptive [12]. After three months of testosterone withdrawal leptin levels 
returned to baseline, which may indicate direct inhibitory effects of testosterone on leptin 
production. We showed at baseline a positive correlation between leptin levels and body weight, 
BMI, and fat mass in our subjects. Similarly to others [13, 14], we did not find a correlation 
between testosterone and leptin levels. The mechanisms of the impact of testosterone on the 
leptin levels are not entirely understood. An indirect effect associated with fat mass reduction 
seems to be obvious. However, also direct effects cannot be ruled out, as indicated in our work 
by the decrease in leptin levels after three months of therapy. Wabitsch et al. in in vitro studies 
on human adipocytes showed an inhibitory effect of testosterone on leptin synthesis and mRNA 
[15]. 
It is well known that high leptin levels increase cardiometabolic risk and adversely affect 
the structure of blood vessels, which can lead to hypertension and atherosclerosis progression 
[16]. A recent meta-analysis showed that high leptin levels may be considered as an 
independent marker of increased risk of myocardial infarction [17]. Moreover, the relationship 
between hyperleptinaemia and development of some cancers was proven [18]. Hence, it must 
be assumed that the decrease in leptin levels in older men during testosterone supplementation 
reduces the risk of insulin resistance, type 2 diabetes, cardiovascular diseases, and the 
development of certain cancers. 
In our study we demonstrate a significant increase in adiponectin levels — over 23% 
after 12 months of therapy with testosterone. Adiponectin is known to exhibit anti-
inflammatory properties and correlates with a decline in fat mass and insulin resistance. Page 
et al. [19] and Frederiksen et al. [20] observed a decrease in adiponectin levels after testosterone 
treatment. Our study is probably the first to demonstrate an increase in the adiponectin levels 
following supplementation of testosterone deficiency. The mechanism of this process is 
complex and involves the direct impact of testosterone on the production of adiponectin and is 
partly a consequence of the fat mass decrease.  
Treatment with testosterone did not significantly affect hsCRP levels when compared 
to placebo in our study, although we noted a decrease in protein levels by 7% after three months 
and by 28% after 12 months among treated patients. Decrease in hsCRP levels may be a 
consequence of a fall of fat mass resulting in lower interleukin 6 production, which is 
considered as responsible for stimulating CRP synthesis. 
We did not observe any serious adverse effects of testosterone therapy. Prostate-specific 
antigen and haematocrit levels increased in the treatment group, but this was an expected effect 
and did not result in the exclusion of any patients from the study. The increase in PSA levels 
occurred in both groups, although only among users of testosterone was it statistically 
significant. The increase can be explained by the physiological process of increasing prostate 
volume associated with male ageing. It is also well known that testosterone treatment may cause 
a slight increase in PSA levels and prostate gland volume [21]. In our study we did not observe 
an increase in PSA above 1 mg/year or values above 4 mg/L. 
The limitation of the study is a small group of subjects, which reduces the statistical 
value of obtained results. However, our work can be used for further, more extensive research 
on hormonal conditioning in aging males. 
 
Conclusions 
Testosterone replacement in men with age-related hypogonadism causes a decrease in 
BMI, fat mass, serum leptin, and CRP levels and increases serum adiponectin levels. 
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Table 1. Baseline characteristics of studied subjects 
 Testosterone  
(n = 20) 
Placebo  
(n = 20) 
p 
Age [y] 56.9 ± 5.7 55.6 ± 5.7 NS 
BMI [kg/m2] 26.6 ± 2.1 26.5 ± 2.6 NS 
BW [kg] 78.3 ± 6.3 78.6 ± 9.5 NS 
FM [kg] 17.0 ± 4.4 19.1 ± 4.9 NS 
FMt [kg] 9.1 ± 2.5 10.1 ± 3.0 NS 
Leptin [µg/L] 6.2 ± 1.4 6.0 ± 2.4 NS 
Adiponectin [µg/mL] 7.6 ± 2.5 7.5 ± 2.7 NS 
hsCRP [mg/L] 1.4 ± 1.2 1.5 ± 1.2 NS 
Testosterone — testosterone-treated group; Placebo — placebo-received group; p — statistical 
significance; BMI — body mass index; BW — body weight; FM — fat mass; FMt — fat mass of the 
trunk; hsCRP — highly selective C-reactive protein; NS — not statistically significant 
 
Table 2. Serum leptin, adiponectin, and highly selective C-reactive protein (hsCRP) levels 
during the 12 months of the study in both groups 
 Group Month 
0 3 6 12 
Leptin 
[g/L] 
Testosterone 6.2 ± 1.4 4.5 ± 
1.5a 
4.3 ± 1.3a 4.0 ± 1.2a, b 
Placebo 6.0 ± 2.4 6.3 ± 
1.8 
7.1 ± 2.1 6.9 ± 2.8 
Adiponectin 
[g/mL] 
Testosterone 7.6 ± 2.5 – – 9.4 ± 2.8a, b 
Placebo 7.5 ± 2.7 – – 6.5 ± 2.1 
hsCRP 
[mg/L] 
Testosterone 1.4 ± 1.2 1.3 ± 
1.1 
– 1.0 ± 1.0a 
Placebo 1.5 ± 1.2 1.3 ± 
1.2 
– 1.6 ± 1.3 
ap < 0.05, compared to initially; bp = 0.001, compared to placebo group 
 
Table 3. Correlations between serum leptin and adiponectin levels and the selected parameters 
before and after 12 months in the testosterone-treated and placebo groups 
 Month 0 Month 12 
Testosterone Placebo Testosterone Placebo 
W P W P W P W P 
L vs. BMI 0.526 0.017 0.739 < 0.01 0.259 NS 0.670 0.001 
L vs. FM 0.530 0.016 0.839 < 0.01 0.523 0.018 0.762 < 0.01 
L vs. FMt 0.555 0.011 0.686 0.001 0.669 0.001 0.629 0.004 
L vs. BW   0.608 0.004   0.585 0.007 
L vs. CRP 0.456 0.043 0.776 < 0.01 0.238 NS 0.608 0.004 
A vs. L –0.548 0.012 –0.587 0.007 –0.333 NS –0.369 NS 
A vs. BMI –0.668 0.01 –0.660 0.002 –0.674 0.001 –0.671 0.001 
A vs. FM –0.411 0.071 –0.473 0.035 –0.395 0.085 –0.466 0.039 
A vs. FMt –0.350 NS –0.381 NS –0.227 NS –0.284 NS 
A vs. CRP –0.549 0.012 –0.779 < 0.01 0.799 < 0.01 –0.669 0.001 
Testosterone — testosterone-treated group; Placebo — placebo group; W — Spearman’s rank 
correlation coefficient; p — value of significance level; L — leptin; A — adiponectin; BMI — body 
mass index; FM — fat mass; FMt — fat mass of the trunk; BW — body weight; CRP — highly selective 
C-reactive protein; NS — not statistically significant  
 
 
Figure 1. Leptin levels [μg/L] in the testosterone-treated and placebo groups 
 
  
Figure 2. Adiponectin levels [μg/mL] in the testosterone-treated and placebo groups 
 
 
 
 
Figure 3. Correlation between adiponectin and leptin before treatment in both groups 
  
